The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation.
Mesoglycan is a preparation of natural glycosaminoglycans, containing mainly heparan sulphate and dermatan sulphate. A clinical trial was conducted to evaluate the efficacy and the tolerability of once-daily mesoglycan in 30 patients with clinical evidence of cerebrovascular insufficiency. Clinical effectiveness was assessed using psychometric and neurological scales: Sandoz Clinical Assessment for Geriatric Patients (SCAG); Parkside Behaviour Rating Scale Modified; Geriatric Depression Scale; and Anxiety Evaluation. Mesoglycan was given as a single oral once-daily dose of 100 mg for a period of 6 months. This treatment was shown to have positive effects on the cognitive and behavioural parameters evaluated. The effects on SCAG were already evident after 3 months' treatment and a significant improvement was observed after 6 months in those patients with a moderate to severe disease. During the treatment period only one patient suffered an adverse reaction attributed to the drug investigated.
Ambrosio
L A
LA
Psychiatric Centre, Annunziata Hospital, Cosenza, Italy.
Marchese
G
G
Filippo
A
A
Romano
E
E
Musacchio
R
R
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001007:Anxiety; D001519:Behavior; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000523:psychology*; D003071:Cognition; D003863:Depression; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales
D006025:Glycosaminoglycans; C040617:mesoglycan